Abbott’s UltiSynq lead receives simultaneous FDA and EU approvals

Abbott announced that its UltiSynq defibrillation lead, which combines conduction system pacing with defibrillation, has been approved by the U.S. FDA and received a CE mark in Europe. The approvals were based on the ASCEND CSP IDE trial, which showed a 97.5% major complication‑free rate and a 98.5% successful implantation rate at three months in 205 patients. Abbott said the lead expands its cardiac rhythm management portfolio.

The dual approvals give Abbott a new product option in both the U.S. and European markets, potentially increasing sales in the large ICD and CRT‑D segments (about 150,000 U.S. and 140,000 European implants annually). The FDA’s breakthrough device designation may accelerate market uptake.

Sources